She was initially treated with low-dose acetylsalicylic acid, with partial improvement, but microvascular symptoms persisted, and platelet counts remained >1,000 × 10⁹/L. Hydroxyurea was initiated, leading to progressive platelet reduction and marked clinical benefit...Cytoreductive therapy may be indicated in cases with extreme thrombocytosis or refractory symptoms, and long-term follow-up is crucial to monitor disease evolution and treatment outcomes. This case highlights the need for multicenter studies and international registries to have pediatric-specific evidence that can better inform diagnostic and therapeutic strategies.

P1, N=161, Active, not recruiting, Massachusetts General Hospital | Trial completion date: Dec 2025 --> Dec 2026

P4, N=160, Active, not recruiting, Children's Mercy Hospital Kansas City | Enrolling by invitation --> Active, not recruiting | Trial primary completion date: Dec 2025 --> Dec 2026

Here, we investigated the therapeutic potential of indomethacin (Indo), a prototypical NSAID, in combination with cyclophosphamide (CTX), a widely used chemotherapeutic agent with immunostimulatory properties. Importantly, Indo retained therapeutic benefit following CTX even in tumors incapable of producing PGE₂, demonstrating a critical contribution of COX-independent mechanisms, particularly inhibition of tumor-intrinsic oncogenic RAS signaling, to the enhanced efficacy of the CTX+Indo combination. Collectively, our results provide strong preclinical rationale for leveraging the COX/PGE 2 and RAS dual inhibitory capacities of NSAIDs to enhance the efficacy of chemotherapy and immunotherapy.

Aspirin suppressed the malignant progression of osteosarcoma by targeting the NF-κB/p65/PDE4D axis, positioning PDE4D as a potential therapeutic target for aspirin- based treatment strategies.

P2, N=117, Active, not recruiting, Canadian Cancer Trials Group | Trial primary completion date: Dec 2025 --> Jun 2026

P=N/A, N=58, Recruiting, The Affiliated Hospital of Putian University

P2/3, N=670, Not yet recruiting, Stanford University

DSigDB database analysis revealed four possible therapeutic drugs for pancreatic cancer: prolinedithiocarbamate, isoliquiritigenin, aspirin, and resveratrol...High-risk pancreatic cancer populations are potentially associated with an immunosuppressive microenvironment. Candidate drugs screened based on LMRGs offer new possibilities for personalized treatment of pancreatic cancer.

The ability to downregulate these cytokines was close to that of aspirin and stronger than that of low concentration LR-AFY02L. By controlling the NF-κB and apoptosis pathways, LR-AFY02 can help reduce intestinal inflammation and prevent the growth of intestinal tumors. These findings suggested that LR-AFY02 may have regulatory effects on colon cancer in mice and merits additional study.

P=N/A, N=950, Not yet recruiting, University of Kansas Medical Center

P1, N=100, Recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial primary completion date: Dec 2025 --> Jul 2026